Media ReleasesImmutep

View All Immutep News


Immutep Announces Positive IMP761 Preclinical Results Presented at 14th Congress of European Crohn’s and Colitis Organisation

SYDNEY, AUSTRALIA – 8 March 2019 - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced positive results from its preclinical study of IMP761, a novel LAG- 3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference in Denmark on 7 March 2019.

Consistent with earlier in vitro studies conducted by Immutep on the immunosuppressive activity of IMP761, this new study in a non-human primate animal model showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen.


For further information please download PDF attached:
Download this document